stilbenes has been researched along with pimagedine* in 3 studies
1 trial(s) available for stilbenes and pimagedine
Article | Year |
---|---|
Aortic wave velocity: a noninvasive method to measure the stiffness of arteries and the clinical results of supplements that appear to improve arterial stiffness.
It has been suggested that arterial stiffness is one of the most important risk factors for the development of a cardiac infarction or stroke. As cardiovascular disease remains the number one killer of individuals before the age of 75, the early detection of cardiovascular disease and its prevention remains paramount in order to sustain a healthy longevity. This article looks at the latest noninvasive technology that can measure arterial stiffness quickly and easily and also highlights a small open trial in which supplements were used to determine their efficacy in helping to reverse/improve arterial stiffness. Topics: Adult; Aged; Aging; Arginine; Cardiovascular Diseases; Carnosine; Dietary Supplements; Female; Glycation End Products, Advanced; Guanidines; Humans; Male; Middle Aged; Pulse Wave Analysis; Resveratrol; Risk Factors; Stilbenes; Vascular Stiffness | 2013 |
2 other study(ies) available for stilbenes and pimagedine
Article | Year |
---|---|
Pharmacological preconditioning with resveratrol: role of nitric oxide.
Resveratrol (trans-3,4',5-trihydroxystilbene), a recently described grape-derived polyphenolic antioxidant, has been found to protect the heart from ischemic-reperfusion injury. The present study sought to determine the mechanism of cardioprotection by investigating the ability of resveratrol to precondition the heart. Isolated perfused rat hearts were randomly divided into six groups: group I was perfused for 15 min with Kreb-Henseleit buffer (KHB) only; group II was perfused with 10 microM resveratrol; group III was perfused with 10 microM resveratrol plus 100 microM N(G)-nitro-L-arginine methyl ester (L-NAME), a nonselective nitric oxide (NO) synthase (NOS) inhibitor; group IV was perfused with 10 microM resveratrol plus 100 microM aminoguanidine (AG), an inducible NOS (iNOS) blocker; and groups V and VI consisted of hearts perfused with L-NAME and AG, respectively. The perfusion was then switched to working mode, and all hearts were made globally ischemic for 30 min followed by 2 h of reperfusion. Preconditioning of the hearts with resveratrol provided cardioprotection as evidenced by improved postischemic ventricular functional recovery (developed pressure and aortic flow) and reduced myocardial infarct size and cardiomyocyte apoptosis. Resveratrol-mediated cardioprotection was completely abolished by both L-NAME and AG. In a separate study, hearts were examined for iNOS mRNA induction. Resveratrol caused an induction of the expression of iNOS mRNA beginning at 30 min after reperfusion, increasing steadily up to 60 min of reperfusion, and then decreasing progressively up to 2 h after reperfusion. Preperfusion of the hearts with AG almost completely blocked the induction of iNOS. The results of our study demonstrate that resveratrol can pharmacologically precondition the heart in a NO-dependent manner. Topics: Animals; Apoptosis; Enzyme Inhibitors; Gene Expression; Guanidines; Heart Ventricles; Ischemic Preconditioning; Malondialdehyde; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Resveratrol; RNA, Messenger; Stilbenes | 2002 |
Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice.
Resveratrol, a natural antioxidant and polyphenol found in grapes and wine, has been found to pharmacologically precondition the heart through the upregulation of nitric oxide (NO). To gain further insight of the role of NO in resveratrol preconditioning, mouse hearts devoid of any copies of inhibitory NO synthase (iNOS) (iNOS knockout) and corresponding wild-type hearts were perfused with 10 microM resveratrol for 15 min followed by 25 min of ischemia and 2 h of reperfusion. Control experiments were performed with wild-type and iNOS knockout hearts that were not treated with resveratrol. Resveratrol-treated wild-type mouse hearts displayed significant improvement in postischemic ventricular functional recovery compared with those of nontreated hearts. Both resveratrol-treated and nontreated iNOS knockout mouse hearts resulted in relatively poor recovery in ventricular function compared with wild-type resveratrol-treated hearts. Myocardial infarct size was lower in the resveratrol-treated wild-type mouse hearts compared with other group of hearts. In concert, a number of apoptotic cardiomyocytes was lower in the wild-type mouse hearts treated with resveratrol. Cardioprotective effects of resveratrol was abolished when the wild-type mouse hearts were simultaneously perfused with aminoguanidine, an iNOS inhibitor. Resveratrol induced the expression of iNOS in the wild-type mouse hearts, but not in the iNOS knockout hearts, after only 30 min of reperfusion. Expression of iNOS remained high even after 2 h of reperfusion. Resveratrol-treated wild-type mouse hearts were subjected to a lower amount of oxidative stress as evidenced by reduced amount of malonaldehyde content in these hearts compared with iNOS knockout and untreated hearts. The results of this study demonstrated that resveratrol was unable to precondition iNOS knockout mouse hearts, whereas it could successfully precondition the wild-type mouse hearts, indicating an essential role of iNOS in resveratrol preconditioning of the heart. Topics: Animals; Apoptosis; Enzyme Inhibitors; Gene Expression; Guanidines; Heart; Ischemic Preconditioning; Kinetics; Male; Malondialdehyde; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxidative Stress; Resveratrol; RNA, Messenger; Stilbenes | 2002 |